
1. cancers (basel). 2018 oct 27;10(11). pii: e404. doi: 10.3390/cancers10110404.

oncolytic viruses canine cancer treatment.

sánchez d(1), cesarman-maus g(2), amador-molina a(3), lizano m(4).

author information: 
(1)unidad de investigación biomédica en cáncer, instituto nacional de
cancerología-instituto de investigaciones biomédicas, universidad nacional
autónoma de méxico, mexico city 14080, mexico. dianasanchezc@hotmail.com.
(2)department hematology, instituto nacional de cancerología, mexico city
14080, mexico. gcesarman@gmail.com.
(3)unidad de investigación biomédica en cáncer, instituto nacional de
cancerología-instituto de investigaciones biomédicas, universidad nacional
autónoma de méxico, mexico city 14080, mexico. aamadorm@incan.edu.mx.
(4)unidad de investigación biomédica en cáncer, instituto nacional de
cancerología-instituto de investigaciones biomédicas, universidad nacional
autónoma de méxico, mexico city 14080, mexico. lizano@unam.mx.

oncolytic virotherapy investigated several decades emerging
as plausible biological therapy several ongoing clinical trials two
viruses approved cancer treatment humans. direct cytotoxicity 
and immune-stimulatory effects make oncolytic viruses interesting strategy for
cancer treatment. review, summarize results vitro in
vivo published studies oncolytic viruses different phases evaluation 
dogs, using pubmed google scholar search platforms, without time
restrictions (to date). natural genetically modified oncolytic viruses were
evaluated encouraging results. studied viruses date the
reovirus, myxoma virus, vaccinia, tested mostly solid tumors as
osteosarcomas, mammary gland tumors, soft tissue sarcomas, mastocytomas.
although results promising, issues need addressing as
ensuring tumor specificity, developing optimal dosing, circumventing preexisting 
antibodies previous exposure development antibodies during
treatment, assuring reasonable safety profile, required in
order make approach successful therapy dogs.

doi: 10.3390/cancers10110404 
pmcid: pmc6266482
pmid: 30373251 

